Slide 1: ASX Announcement: Investor presentation
ASX ANNOUNCEMENT 17 February 2022 Investor presentation For personal use only 17 February 2022 – As announced on 16 February 2022, Cann Group Limited (ASX: CAN) (Cann or the Company) will be presenting an investor update webinar and Q&A with CEO Peter Crock, COO Shane Duncan and CFO Deborah Ambrosin
Slide 2: Half Year 2022 Update
For personal use only HALF YEAR 2022 UPDATE February 2022 Cann Group Limited ABN 25 603 949 739
Slide 3: Disclaimer | Important Notice
DISCLAIMER | IMPORTANT NOTICE This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann). For personal use only Summary information This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentat
Slide 4: Agenda
AGENDA For personal use only 1 Financial results 2 Commercial operations 3 Mildura facility 4 Regulatory progress 5 Satipharm update 6 Industry status 7 Outlook for H2 2022 8 Pillars of growth
Slide 5: Financial Results
For personal use only RESULTS FINANCIAL
Slide 6: Financial Results
1. FINANCIAL RESULTS 1H 2022 1H 2021 • Revenue generated from customers For personal use only $ Mvt % Mvt $000’s $000’s was $3.2m representing an increase of 193% to the prior corresponding Revenue from operating activities 3,172 1,081 2,091 193.4% period. Other income 2,970 4,150 Operating expenses
Slide 7: Commercial Operations
For personal use only OPERATIONS COMMERCIAL
Slide 8: Summary of Commercial Operations
2. SUMMARY OF COMMERCIAL OPERATIONS • Significant increase in sales and production half on half. For personal use only • B2B model gaining momentum with multiple new supply agreements. • Upgrade of Southern facility allows production and distribution of Active Pharmaceutical Ingredient (API) and med
Slide 9: Commercial Update | Production
2. COMMERCIAL UPDATE | PRODUCTION • GMP manufacturing has commenced on dried flower For personal use only orders received in the first half of FY22. • Significantly increased the number of customers in first half. • Cann delivered 15,918 oil bottles in first half of FY22 vs 2,856 oil bottles first h
Slide 10: Commercial Update | GMP Manufacture
2. COMMERCIAL UPDATE | GMP MANUFACTURE • TGA licence granted for For personal use only Southern facility in January 2022 • Provides ability to produce cGMP packed flower at substantial cost saving over third-party supply • Strong demand for high THC GMP packed dried flower in patient-ready forms • I
Slide 11: Mildura Facility
For personal use only FACILITY MILDURA
Slide 12: Mildura Facility
3. MILDURA FACILITY • Construction substantially complete – handover from principal building contractor expected in For personal use only coming weeks. • Commissioning of lab and production suites is complete and laboratory is fully operational. • On-site ODC inspection has been completed and Mildur
Slide 13: Mildura | Laboratory Operational
3. MILDURA | LABORATORY OPERATIONAL For personal use only
Slide 14: Mildura | Manufacturing Suites Operational
3. MILDURA | MANUFACTURING SUITES OPERATIONAL For personal use only
Slide 15: Mildura | Cultivation Facility Progress
3. MILDURA | CULTIVATION FACILITY PROGRESS For personal use only
Slide 16: Mildura | Expected Milestones Over Second Half FY22
3. MILDURA | EXPECTED MILESTONES OVER SECOND HALF FY22 For personal use only March 2022 – June 2022* Mother plants onsite First commercial crop First commercial crops harvest Satipharm capsule commercial commence TGA GMP licences issued production commences GMP large scale extraction Large scale ext
Slide 17: Regulatory Progress
For personal use only PROGRESS REGULATORY
Slide 18: Regulatory Progress
4. REGULATORY PROGRESS Southern facility For personal use only • TGA GMP manufacturing licence granted • Operational for shipment and sale of dried flower • GMP manufacturing has commenced Mildura facility • ODC and TGA inspections completed for laboratory, extraction and manufacturing – licences an
Slide 19: Satipharm Update
For personal use only SATIPHARM UPDATE
Slide 20: Satipharm Product Registration
5. SATIPHARM PRODUCT REGISTRATION • S3 registration process on track, dossier preparation advancing. For personal use only • Ethics Committee approval granted February 2022. • Pre-submission meeting held with TGA. • Clinical trial product released and ready for patient supply. • Clinical trial sites
Slide 21: Satipharm Update
5. SATIPHARM UPDATE • Expanding Satipharm distribution in Australia and UK/Europe – with other markets now in focus For personal use only • Expanding product range • Manufacturing line delivered & installed at Mildura facility, manufacture of initial batches has commenced • A proprietary technology
Slide 22: Industry Status
For personal use only STATUS INDUSTRY
Slide 23: Industry Status
6. INDUSTRY STATUS Australian Medicinal Cannabis Market Key Highlights* For personal use only • Medicinal cannabis revenue (from patients) expected to exceed expectations in 2021, hitting the $200m mark. • Patient numbers have grown by a factor of 15x over the past two years. • Slow-down in delivery
Slide 24: Industry Status: Opportunities for Cann
6. INDUSTRY STATUS Opportunities for Cann For personal use only • Cann is well placed to capitalise on a rapidly growing market in Australia in 2022. • Increased manufacturing capacity coming online, expanded cGMP product range that includes dried flower, oil and capsule finished dose forms. • Expan
Slide 25: Outlook for H2 2022
For personal use only FOR H2 2022 OUTLOOK
Slide 26: Outlook for H2 2022
7. OUTLOOK FOR H2 2022 • Sales and production momentum to continue, both domestic and international. For personal use only • Regulatory licences expected to be in place. • Mildura facility to commence production and release first commercial crop. • Southern GMP manufacturing to increase. • Clinical
Slide 27: Pillars of Growth
For personal use only GROWTH PILLARS OF
Slide 28: Pillars of Growth
8. PILLARS OF GROWTH Cann Group For personal use only Capacity & Domestic & International Path to Registered Innovative Product Capability Business Development Products Pipeline • Efficiently scalable to • BD team in Europe • S3 Registration program • R&D program, plants meet growing demand • Strate
Slide 29: Contact
For personal use only CONTACT Pe te r Cro c k CEO Cann Group Limited +61 3 9095 7088 peter.crock@canngrouplimited.com